

non-CVD Women

non-CVD Men

			1 40- 12
GLYCOLYSIS-E-D			1.48e-12
PWY-5154	<b>⊢</b> −●−−1	1	9.64e-11
PWY-5971			2.79e-8
POLYISOPRENSYN-PWY		1	1.91e-13
PWY-6897	<b>⊢_●</b>		1.65e-12
PWY0-1297			2.09e-14
PWY0-781			3.93e-13
PWY-1269		I	8.25e-9
HOMOSER-METSYN-PWY			2.62e-10
PWY-5384			< 1e-15
PWY-6507	<b>⊢</b> −−−1		3.88e-7
P161-PWY			2.32e-5
PWY-5913	<b>⊢</b> −−−−	-	7.60e-5
TCA	<b>⊢</b> −−−−	I	4.32e-7
PANTO-PWY	<b>⊢</b> −●−−1	I	8.65e-10
UDPNAGSYN-PWY			7.55e-7
SULFATE-CYS-PWY			5.11e-8
GLUCONEO-PWY	⊢		5.77e-15
PWY-6470		НОН	< 1e-15
HISDEG-PWY	⊢	I	2.65e-7
POLYAMSYN-PWY			2.22e-15
PWY-6892	<b>⊢</b>		1.24e-6
PYRIDOXSYN-PWY	<b>⊢</b> −●−−−		4.68e-7
P105-PWY			1.87e-5
PWY-5838			8.44e-9
PWY-6612	<b>⊢_●</b>	I	1.79e-8
PWY-5840			6.00e-9
RIBOSYN2-PWY	<b>⊢</b> ●	I I	4.09e-10
PWY0-1298			1.22e-6
P441-PWY			4.82e-10
PWY-7242	<b>⊢</b> −−−−1	I	7.82e-6
FOLSYN-PWY	<b>⊢</b> ●––1	I	2.62e-9
RHAMCAT-PWY	<b>⊢</b>	1	1.67e-5
PWY-5898			8.70e-9
PWY-5899			8.70e-9
PWY-5897			8.70e-9
KDO-NAGLIPASYN-PWY			1.87e-7
PWY-6737	<b>⊢</b>		6.23e-6
PYRIDNUCSAL-PWY	●		6.66e-8
PWY-6545			3.17e-10
PWY-6121		·	6.64e-10
PWY0-845	<b>⊢●</b>	1	1.00e-5
HEXITOLDEGSUPER-PWY			7.02e-9
PWY0-862			2.17e-4
PWY-6122	·●1		2.99e-8
PWY-6277			2.99e-8
PWY-6700		I	8.17e-5
PWY-5861			1.82e-8

n	on-CVD Women	non-CVD M	en
PANTOSYN-PWY	⊢-●	1	3.48e-8
PWY-5695	<b>⊢_●</b>	1	2.64e-6
NONMEVIPP-PWY	<b>⊢</b> ●	I	5.46e-7
PWY-7560		1	5.46e-7
PWY-5973	<b>⊢</b> −−1		7.47e-9
PWY-7211	<b>⊢</b>	1	1.33e-5
PWY-7664			1.88e-3
PWY-5005			5.73e-9
PWY-7377			6.70e-8
PWY-5850			1.83e-8
PWY-5896		$\vdash \bigcirc \dashv$	1.83e-8
PWY-5845			1.85e-8
PWYG-321			2.95e-3
HSERMETANA-PWY			7.28e-5
FERMENTATION-PWY			9.34e-5
PWY-5484	⊢	1	7.30e-4
HISTSYN-PWY	<b>├</b> ─●──┤		6.84e-5
PWY-7663	⊢-●	l	6.27e-7
PWY0-1261	├──●──┤	I	6.07e-3
THRESYN-PWY	<b>⊢</b> ●		7.84e-8
SO4ASSIM-PWY		$\vdash \bigcirc \dashv$	1.20e-7
PWY-5989			2.68e-3
PWY-6282			2.47e-3 y
PWY-7003			2.47e-3 a 2.01e-10 b 6.34e-4 b
PWY-5101			6.34e-4 🕁
PWY-7199	⊢_●		3.45e-5
ALL-CHORISMATE-PWY		$\vdash \bigcirc \dashv$	5.56e-8
GLYCOLYSIS-TCA-GLYOX-BYPASS			3.08e-5
PWY-6317			6.90e-4
ANAGLYCOLYSIS-PWY	⊢_●		1.92e-6
PWY-6588			2.73e-5
PWY-3001	⊢-●1		5.55e-6
PWY-5676			5.87e-9
GLUTORN-PWY	⊢_●	I	1.88e-4
GLYCOLYSIS	⊢		7.48e-5
PWY-5121	<b>⊢</b> ●		4.80e-5
ENTBACSYN-PWY		H-0-1	4.16e-9
P124-PWY			8.10e-10
PWY-6703	⊢	I	1.15e-3
PWY0-1241			1.03e-9
1CMET2-PWY	⊢-●1		1.39e-7
GLUCOSE1PMETAB-PWY			2.44e-9
PWY-5104	<b>⊢</b> −●−−−1		4.26e-4
FASYN-INITIAL-PWY			2.15e-3
P4-PWY			1.37e-5
PWY-5097	⊢●─┤		1.09e-5
PWY-5860			4.23e-8
PWY-5862			4.25e-8

non	-CVD Women	non-CVD Men	
PWY-6123	⊢_●	1	3.15e-4
PWY-6353			2.32e-5
PWY-6126	<b>⊢</b> ●		1.18e-5
DAPLYSINESYN-PWY			9.98e-3
PWY-5863			5.52e-8
BRANCHED-CHAIN-AA-SYN-PWY		1	4.72e-4
OANTIGEN-PWY			3.87e-4
PPGPPMET-PWY			1.68e-6
PWY-7219	<b>⊢</b>		5.54e-4
PWY-6519			0.015
PWY-2942	⊢-●		3.37e-5
PWY-841	<b>⊢</b> ●	I	1.54e-4
PWY-7222	<b>├</b> ─●──┤	I	3.99e-3
PWY-7220	<b>⊢</b> ●		3.99e-3
PWY490-3		ю	1.55e-15
PWY-7229	<b>⊢●</b>	1	7.02e-5
SALVADEHYPOX-PWY			1.25e-3
PWY-5837			1.01e-7
PWY4FS-8			6.61e-3
PWY4FS-7			6.61e-3
PWY-7196	<b>⊢</b> −●−−−	1	8.40e-3
BIOTIN-BIOSYNTHESIS-PWY			0.019
DENOVOPURINE2-PWY	<b>⊢</b> ●	1	2.84e-4
PWY-6163	<b>⊢●</b>	1	1.27e-4
PWY-5103	<b>⊢</b>		3.44e-3
PWY-5910		і I Ю	< 1e-15
COA-PWY	<b>⊢</b> ●1	l.	3.41e-4
PWY-5686		1	1.47e-3
REDCITCYC			1.57e-3
PWY-7187			2.21e-6
PENTOSE-P-PWY	<b>⊢</b>	4,	0.033
P461-PWY			6.88e-5
PWY-5345			2.19e-3
PWY0-162	<b>⊢</b> ●	I	3.28e-3
PWY-6608			5.97e-3
TRNA-CHARGING-PWY	<b>⊢●</b>	1	6.70e-4
GALACTUROCAT-PWY	<b>⊢</b> −−+	1	0.011
VALSYN-PWY	<b>⊢</b> − <b>●</b> −−	I	7.61e-3
ILEUSYN-PWY	<b>⊢</b> −−−		7.61e-3
PWY0-166			2.61e-6
PWY-7221		1	2.13e-4
P122-PWY			4.37e-9
POLYAMINSYN3-PWY		I HOH	1.83e-11
PWY-7184			8.67e-6
PWY-621			9.26e-3
SER-GLYSYN-PWY			2.15e-3
PWY-7228	<b>⊢</b> ●		3.50e-3
TRPSYN-PWY	<b>⊢</b> ●	1	2.56e-3

non-CVD Men

PWY-6125				3.28e-3
TCA-GLYOX-BYPASS		$\vdash \circ \dashv$		9.00e-5
CALVIN-PWY		⊢●→		1.12e-3
PWY-7197		⊢ <b>●</b> ⊣ ∣		0.014
PWY-2941				1.28e-6
PWY-6629		⊢●→││		3.15e-5
PWY-6901		⊢ <b>−</b> ●−−−		0.030
GLCMANNANAUT-PWY				6.09e-4
GLUCUROCAT-PWY				1.14e-3
PWY-922		i Koi		< 1e-15
ECASYN-PWY		I HOH		1.25e-6
PEPTIDOGLYCANSYN-PWY		⊢ <b>●</b> ⊣¦		0.010
NONOXIPENT-PWY		<b>⊢_</b> ●		0.035
GALACT-GLUCUROCAT-PWY				2.64e-3
PWY-6263				2.89e-4
LACTOSECAT-PWY		M		< 1e-15
PWY-6891		¦ ⊢0−1		2.70e-3
PWY-5100				0.027
PWY-6387		<b>⊢</b> ●		0.019
PWY-6749				2.71e-3
FAO-PWY				0.013
PWY-6385				0.023
PWY-7315		<b>⊢</b> 0−1		5.42e-3
PWY-7208		<b>⊢</b> ● –		0.057
CODH-PWY		H●H i		8.22e-9
COLANSYN-PWY				0.013
1				
-0	.10 -0.05	0.00	0.05	0.10
	DIΠ	erence in mean proportion	5 (70)	

Figure S1. Functional characterization between CHD patients according to the sex based on PICRUSt2 analysis.